Newtyn Management’s Collegium Pharmaceutical COLL Stock Holding History

Newtyn Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100,000	Closed	-$2.4M	–	55
2023 Q1	$2.4M	Sell	100,000 -5,000	-5%	-$133K	0.47%	44
2022 Q4	$2.44M	Hold	105,000	–	–	0.5%	37
2022 Q3	$1.68M	Hold	105,000	–	–	0.37%	42
2022 Q2	$1.86M	Buy	+105,000	New	+$1.77M	0.35%	44

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Newtyn Management's COLL Position: Q2 2023 in Review

Newtyn Management sold out of Collegium Pharmaceutical (COLL) in Q2 2023, closing a stake of 100,000 shares — an estimated $2.4M sold.

Newtyn Management first reported a position in COLL in Q2 2022 and held it in 4 quarters. The position peaked at $2.44M in Q4 2022. 178 funds tracked by Wall St. Rank hold COLL as of Q2 2023.

Newtyn Management reported no remaining Collegium Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Newtyn Management sold 100,000 Collegium Pharmaceutical shares in Q2 2023, an estimated $2.4M.
Newtyn Management first reported a position in Collegium Pharmaceutical in Q2 2022 and held it in 4 quarters.
Newtyn Management's Collegium Pharmaceutical position peaked at $2.44M in Q4 2022.
178 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.